Tinengotinib (TT-00420) is A novel multikinase inhibitor that strongly inhibits Aurora A/B with IC50 values of 1.2/3.3 nM, respectively. It also shows potent inhibitory activity against FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R and can be used to treat triple-negative breast cancer (TNBC).

 

Brand: BCM

 

Boiling Point: 665.9±55.0 °C(Predicted)

 

pKa: 16.32±0.40(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

Isomeric SMILES: CC1=C2C(=NN1)NC3=CC(=NC=C3C(=N2)C4=CC=CC=C4Cl)N5CCOCC5  

 

InChIKey: DQFCVOOFMXEPOC-UHFFFAOYSA-N  

 

InChI: InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26) 

 

Attribute
[Chem Name]	4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-1(14),3,6,8,10,12-hexaen-13-yl]morpholine
[Synonym]	Tinengotinib; TT-00420
[CAS No.]	2230490-29-4
[Formula]	C20H19ClN6O
[Molecular]	394.86
[Form]	Solid Powder
[Storage]	Stored at -20°C

Goods Tag